Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 15, 2005Cancer ResearchOpen Access

High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor

View Full Paper
Ask AI
Bookmark
Share

Authors

NFNobukazu FujimotoOkayama Rosai HospitalMWMarie WislezInsermJZJie ZhangJilin University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fujimoto et al. (2005) studied this question.

synapsesocial.com/papers/6a9f009ebcc17daa429615c0https://doi.org/10.1158/0008-5472.can-05-1977
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy2004 · 9,463 citations
  2. 2The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation2003 · 967 citations
  3. 3KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib2005 · 1,528 citations
  4. 4Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer2005 · 440 citations